S
ystemic typhoidal Salmonella enterica (serovars Typhi and Paratyphi) has been a major focus of study in the scientific community for the last several decades. Significant progress has been made regarding vaccine development against these serovars, which led to the production of two commercially available typhoid vaccines (1) . However, there is still room for improvement regarding the efficacy of these vaccines, especially for targeting younger children. More recently, nontyphoidal S. enterica (NTS; other serovars) infections emerged as a significant, clinically important disease in developing countries, being a major cause of invasive infections, particularly in Africa, where it can be isolated from up to 50% of all bacteremias. Recently, NTS have been shown to be as commonly isolated from bacteremias as Haemophilus influenzae type b and pneumococcus in sub-Saharan Africa (2), highlighting the importance of vaccine development to control this disease in endemic areas. In PNAS, Lee et al. (3) make a significant contribution toward the future development of effective vaccines against Salmonella. The authors describe the construction and use of a Salmonella proteomic array to identify a common immune signature of bacterial antigens in mice and humans with bacteremia caused by Salmonella, defining an approach to identify potential candidates for a subunit vaccine.
Protein Arrays as a Tool for Antigen Discovery Protein arrays have been used to detect seroreactive peptides in several infectious agents (4) (5) (6) (7) . This approach has been shown to be a fast, efficient, and accurate alternative to detect antigens compared with traditional methods, such as mass spectrometry and Western blots (8) . It has the advantage of enabling the screening of a large number of potential antigens and detecting them independently of their natural abundance during infection and without prior knowledge of their immunogenicity. Although useful, one important limitation of protein arrays is their inability to identify nonprotein antigens. This shortcoming has just started to be overcome through the development of arrays that are able to incorporate molecules such as carbohydrates and polysaccharides (9, 10) . Protein conformation and posttranslational modifications important for specific antibody interactions may also be difficult to detect using this approach. Nevertheless, proteomic arrays provide an integrated understanding of the antibody repertoire generated in response to an infection, improving our knowledge of the immune Lee et al. make a significant contribution toward the future development of effective vaccines against Salmonella.
response and protection against any given infectious agent. This approach can provide better serodiagnostic tools, be used in epidemiological research and, as illustrated here, can be used for the discovery of potential antigens for future vaccine development.
Antigen Recognition for Salmonella Vaccine Development
The measurement of antibodies generated in response to an infection or immunization is frequently used to gauge protection, as observed by passive immunization with antibodies. Because protection against invasive Salmonella in both mice and humans is mediated through the antibody response, Lee et al. examined antigen targeting of IgG after immunization (3). In this study, sera from four different strains of Salmonellainfected mice were used to probe a Salmonella proteomic array. This approach revealed more than 100 antigens recognized after Salmonella immunization. Of these, a group of 29 antigens was present in at least three of the four strains of mice commonly used in Salmonella research. Common antigen targets in the majority of mouse strains included proteins previously shown to be protective against Salmonella infections, such as OmpA and FliC, validating the array as a tool to find potential vaccine candidates, as well as the use of experimental mice in preclinical studies. A number of antigens were shown to be recognized during Salmonella infection and have the potential to be further studied regarding their protection against NTS infections. Sera from a group of children with systemic salmonellosis, most of which presented with invasive NTS bacteremia, were also used to probe the proteomic array, and this identified an overlap of antigen recognition between murine and human samples. One of these antigens targeted by human serum, SseB, was shown to be protective against infection in mice, further confirming the use of the mouse model in preclinical studies. More importantly, it validated the use of this proteomic array in finding potential candidates for the development of subunit vaccines for human use.
Future Steps for Vaccine Development Against Invasive Salmonella
Typhoid fever remains an important cause of morbidity, with 22 million cases and 200,000 deaths per year worldwide, with most cases happening in Africa, Asia, Latin America, and Oceania (11).
Invasive NTS disease has also emerged as a burden in global health, with mortality rates reaching up to 25% in Africa (12) . Underlying risk factors for NTS infections are very young age, malaria anemia, malnourishment, and HIV infection (12) . Antimicrobial resistance among clinical invasive Salmonella isolates in Africa is increasingly common, making treatment of these infections even more difficult (13) . The lack of vaccines against invasive NTS is concerning, and efforts toward their development should be a priority in the control of these infections in both developed and developing countries (13, 14) . Although vaccines against typhoid Salmonella are available, their use and effectiveness is questionable, and this disease continues to be a burden in many developing countries (1) . This study provides an approach that could be used to identify antigens for the improvement of the current typhoid vaccines, as well as for future vaccine development against systemic salmonellosis in general. The antigens described here now need to be systematically studied to provide significant data to warrant vaccine development. In the future, the proteomic array developed should be used to test a larger number of typhoid sera and unveil new targets for the improvement of the efficacy of current vaccines. Overall, the study of a larger cohort of clinical samples will enhance the potential impact of developing an effective vaccine, providing more comprehensive data regarding the overlapping antigen targeting among patients, as well as a better understanding of the responses to infection, hopefully culminating in new and improved Salmonella vaccines. 
